Minocycline topical- BioPharmX Corporation

Drug Profile

Minocycline topical- BioPharmX Corporation

Alternative Names: BPX-01

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator BioPharmX Corporation
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne

Most Recent Events

  • 04 Jan 2017 BioPharmX Corporation completes enrolment in the OPAL phase IIb trial for Acne vulgaris in USA
  • 04 Jan 2017 BioPharmX Corporation plans a phase III trial for Acne vulgaris
  • 25 Oct 2016 BioPharmX plans a phase II trial for Acne vulgaris (In adults) in USA (Topical) (NCT02946788)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top